

## Cell Line Data Sheet for CHLA-140

**Disease:** Neuroblastoma  
**Phase of Therapy:** Post-Diagnosis (Progressive Disease)  
**Treatment:** N/A  
**Disease Stage:** 4  
**Gender:** Male  
**Age at diagnosis:** N/A  
**Race:** N/A  
**Age at sample collection:** N/A  
**Source of Culture:** Bone marrow  
**Primary Tumor Site:** N/A  
**Date Established:** December 1993

**MYCN Patient:** N/A  
**MYCN Cell line:** N/A  
**TH mRNA:** Expressed  
**p53 functionality:** N/A  
**Telomere Mechanism:** N/A  
**ALK:** N/A  
**RNAseq:** N/A  
**WES:** N/A

**IC90 (DIMSCAN\*):**  
 \*see reference 5

CBDCA (µg/ml)	CDDP (µg/ml)	DOX (ng/ml)	ETOP (ng/ml)	L-PAM (µg/ml)
1.1	0.2	1.1	0.2	1.5

CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan

**Growth Conditions:** Please see Protocols section at <https://www.cccells.org/protocols.php>  
 5% CO<sub>2</sub>, 20% O<sub>2</sub>, 37.0°C

**Media Formulation:** Please see Protocols section at <https://www.cccells.org/protocols.php>  
 Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

**Doubling Time:** N/A  
**Growth Properties:** Adherent and suspended cells, grows mostly in clumps

**STR Profile:** May be obtained at <https://strdb.cccells.org/>

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis



---

## Cell Line Data Sheet for CHLA-95

---

**Cell Line Name:** CHLA-95

**References:**

2. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma. *Cancer Res.* 61, 679-686, 2001. PubMed ID: [11212268](https://pubmed.ncbi.nlm.nih.gov/11212268/)  
<https://cancerres.aacrjournals.org/content/61/2/679.long>
3. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide. *J Natl Cancer I.* 99: 1107-19, 2007. PubMed ID: [17623797](https://pubmed.ncbi.nlm.nih.gov/17623797/)  
<https://academic.oup.com/jnci/article/99/14/1107/938992>
4. Maurer BJ, Kalous O, Yesair DW, Wu X, Vratilova J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP: Improved oral delivery of N-(4-hydroxyphenyl)retinamide with novel LYM-X-SORBTM organized lipid complex in mice. *Clin Cancer Res.* 13:3079-3086, 2007. PubMed ID: [17505011](https://pubmed.ncbi.nlm.nih.gov/17505011/)  
<https://clincancerres.aacrjournals.org/content/13/10/3079.long>
5. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatr Blood Cancer.* 56: 239-249, 2011. PubMed ID: [20922763](https://pubmed.ncbi.nlm.nih.gov/20922763/)  
([www.PPTPinvitro.org](http://www.PPTPinvitro.org))  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/>







## Cell Line Data Sheet for CHLA-95

Cell Line Name: CHLA-95


(10x magnification)



(10x magnification)



(20x magnification)



(20x magnification)

